CJC-1295 with DAC 5mg + Ipamorelin 5mg

Research

Blend composed of CJC-1295 DAC and Ipamorelin, a synergistic combination widely used in research models on growth hormone (GH) modulation.

Scientific Research on CJC-1295 with DAC 5mg + Ipamorelin 5mg

This blend combines two growth hormone secretagogues (GHS) that act through distinct and complementary pathways. CJC-1295 with DAC is a long-acting GHRH (Growth Hormone-Releasing Hormone) analog, while Ipamorelin is a highly selective ghrelin mimetic (GH secretagogue receptor agonist). The 5mg+5mg presentation is common in lyophilized research vials for studies on hormonal synergy.

Mechanism of Action and Inhibition

The blend operates through a "clamp mechanism" on the pituitary somatotroph:

• CJC-1295 DAC: Acts by binding to GHRH receptors, stimulating basal GH synthesis and release. The DAC complex allows the peptide to bind to serum albumin, extending its activity.
• Ipamorelin: Acts on ghrelin receptors (GHS-R1a), mimicking the natural pulse of GH release. Its selectivity avoids increases in cortisol and prolactin, which are common with other GHRPs.
• Synergy: The presence of a GHRH analog (CJC) significantly potentiates the response to the GHS (Ipamorelin), resulting in greater GH release than the sum of the individual parts.

Metabolic Impacts Already Scientifically Investigated

1. Body Composition: Increased lipolysis (fat burning) and promotion of muscle protein synthesis.
2. Bone Mineral Density: Improved calcium retention and bone mineralization via IGF-1 signaling.
3. Tissue Repair: Accelerated recovery from soft tissue injuries and improved deep sleep quality (slow-wave phase).

Investigation in Oncological Models

The increase in systemic GH levels and consequently IGF-1 (Insulin-like Growth Factor 1) is the central focus in experimental oncology:

• Cell Proliferation: Elevated IGF-1 levels may theoretically accelerate the proliferation of pre-existing neoplastic cells.
• Contraindication in Research: Models presenting active tumors or genetic predisposition to hormone-dependent neoplasms are generally excluded from studies with this blend due to the risk of stimulating tumor growth.

Specific Action of the CJC-1295 + Ipamorelin Blend

The specific action of this blend is the amplification of GH pulsatility. While CJC-1295 with DAC ensures that the GH "reservoir" is always ready and elevated, Ipamorelin forces the release of this GH in a pulsatile manner, mimicking the natural biological rhythm more potently without rapidly desensitizing the receptors.

Pharmacokinetic Considerations in Research

• CJC-1295 DAC: Has a long half-life, estimated at approximately 6 to 8 days, due to albumin binding.
• Ipamorelin: Has a short half-life, approximately 2 hours, requiring more frequent administrations or specific timing.
• Bioavailability: Both are sensitive to gastric degradation and are typically studied via subcutaneous administration to ensure plasma stability.

Other Important Research-Related Considerations

The relationship between this blend and insulin sensitivity is relevant. Although GH can induce insulin resistance at high doses, the selectivity of Ipamorelin and the more stable release of CJC-1295 aim to minimize this negative metabolic impact compared to synthetic exogenous GH.

Final Considerations

The CJC-1295 DAC + Ipamorelin combination is one of the most effective tools for studying systemic regeneration and anti-aging in biological models. The synergy between constant stimulation (CJC) and pulsatile stimulation (Ipamorelin) offers a superior efficacy profile, although it requires rigorous monitoring of IGF-1 levels and cellular integrity.

References

• Sigalos, J. T., & Pastuszak, A. W. (2024). The Safety and Efficacy of Growth Hormone Secretagogues. Translational Andrology and Urology, 13.
• Alba, M., & Fintini, D. (2023). Effects of Ipamorelin, a Selective GH Secretagogue, on Somatotroph Function. Journal of Endocrinology, 258.
• Myong, S., Nguyen, A., & Challa, S. (2024). Biological functions and therapeutic potential of NAD+ metabolism in gynecological cancers. Cancers, 16. https://doi.org/10.3390/cancers16173085.